Grey - after consultant/specialist initiation, Red, Green, Green - after consultant/specialist initiation
Decision Date:


RED:1,5 NICE TA170: prevention of VTE after hip or knee replacement in adults

GREEN: NICE TA256: anticoagulant option in AF patients as per local guidance (decision date - July 2012)

GREEN (following specialist initiation): for the following indications as per SPC:

  • NICE TA261: Venous thromboembolism (treatment and long-term secondary prevention).  Rivaroxaban - a recommended option for treating DVT, and to help prevent a pulmonary embolism or another DVT.  (Decision date - March 2013)
  • NICE TA287: for treating pulmonary embolism and preventing recurrent venous thromboembolism (decision date - August 2013)
  • 2.5mg preparation. NICE TA335: GREEN specialist initiation for patients commenced on rivaroxaban 2.5mg tablet, with a specified 12 month stop date. Indicated as per NICE TA335: preventing adverse outcomes after acute management of acute coronary syndrome. (Decision date May 2015, further decision – August 2023)

GREY 3,6 after consultant/specialist initiation: NICE TA607: Rivaroxaban 2.5mg + aspirin for the prevention of atherothrombotic events in people with coronary or peripheral artery disease. Treatment should only be started after an informed discussion with the patient about the risks and benefits of treatment. (Decision date - November 2019)


Grey Drug Classifications

  • 3: Known excess of significant adverse events compared with standard therapy
  • 6: NICE guidance

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 5: Is new to clinical practice and unfamiliar, necessitating a period of accumulation of experience, firstly (and most rapidly) by consultants/specialists

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app